Stock Screener App

Frei - Play StoreApp Store

Installieren Installieren

Dow:

Nasdaq:

S&P 500:

NSRX

$3.073.76%-0.12

Nasus Pharma Ltd. (NSRX)

Date: O: H: L: C: Vol:

Nasus Pharma Ltd. Aktie (NSRX) Neueste Nachrichten

Is Nasus (NSRX) Still a Buy After +8.05% Rally? 2026-10-26 - Max Pain Level - https://www.dars.gov.et/

Nasus Pharma Ltd. Estimates – AMEX:NSRX - TradingView

At the October 8 meeting, Nasus Pharma (NSRX) shareholders approved all agenda items except one. - Stock Titan

Nasus Pharma stock reiterated at Market Outperform by Citizens - Investing.com South Africa

Nasus Pharma stock reiterated at Market Outperform by Citizens - Investing.com Nigeria

Nasus Pharma stock reiterated at Market Outperform by Citizens - Investing.com

Nasus Pharma stock reiterated at Market Outperform by Citizens - Investing.com UK

Nasus Pharma enrolls first patient in NS003 phase 1 trial - Investing.com

Nasus Pharma Enrolls First Patient in Phase 1 PK Trial of NS003 Intranasal Ondansetron for CINV and PONV - Quiver Quantitative

Nasus Pharma Announces Enrollment and Dosing of First - GlobeNewswire

Nasus Pharma enrolls first patient in NS003 phase 1 trial By Investing.com - Investing.com UK

Nasus Pharma CFO Eyal Rubin Resigns, Files Ownership Disclosure - kalkinemedia.com

Rubin Eyal ceases as CFO at Nasus Pharma (NSRX) - Stock Titan

New Nasus Pharma (NYSE: NSRX) share plan could dilute holders while funding anaphylaxis drug trials - Stock Titan

Nasus Pharma (NSRX) taps BTIG to sell new shares for drug trials - Stock Titan

FDA clears nasal epinephrine study for Nasus Pharma (NSRX) targeting anaphylaxis - Stock Titan

Nasus Pharma Announces FDA Clearance to Initiate Clinical Study of NS002 in the Treatment of Anaphylaxis - GlobeNewswire

Nasus Pharma Ltd SEC Filing (Sep 14, 2026) - Stock Titan

Nasus Pharma Announces FDA Clearance to Initiate Clinical Study of NS002 in the Treatment of Anaphylaxis - Yahoo Finance

Nasus Pharma to Participate in the H.C. Wainwright 28th Annual Global Investment Conference - Yahoo Finance

Nasus Pharma to Present at H.C. Wainwright 28th Annual Global Investment Conference - Quiver Quantitative

A company developing nasal allergy medicine will present in New York - Stock Titan

Nasus Pharma to Participate in the H.C. Wainwright 28th Annual Global Investment Conference - GlobeNewswire

Nasus Pharma Sets October 8, 2026 Shareholder Meeting to Vote on Governance, Executive Pay and Option Pool - The Globe and Mail

A $750,000 sale bonus? Nasus Pharma (NSRX) puts CEO pay to a shareholder vote - Stock Titan

Nasus Pharma (NYSE: NSRX) sets $50M share shelf for working capital and drug development - Stock Titan

Nasus Pharma Files $50 Million Shelf Registration - Yahoo Finance

Nasus Pharma Announces Transition of Chief Financial Officer - Yahoo Finance

Nasus Pharma (NSRX) CFO exit ushers in long-time insider as interim - Stock Titan

Nasus Pharma Reports First Half 2026 Financial Results and Provides Business Update - GlobeNewswire

Nasus Pharma Reports First Half 2026 Financial Results and Provides Business Update - Yahoo Finance

Nasus Pharma Appoints Pharmaceutical Industry Veteran - GlobeNewswire

Nasus Pharma (NYSE American: NSRX) taps Brendan O’Grady to lead next phase - Stock Titan

A new CEO takes charge as Nasus Pharma advances nasal anaphylaxis treatment - Stock Titan

NSRX Forecast — Price Target — Prediction for 2027 - TradingView

Nasus Pharma Announces Positive Results from Preclinical - GlobeNewswire

NSRX - Finviz

NSRX: Initiating Coverage – Sniffing Out a Better Solution - Yahoo Finance

Nasus Pharma to Participate in Upcoming Investor Conferences - Yahoo Finance

Nasus Pharma to Participate in Upcoming Investor Conferences - Moomoo

Nasus Pharma to Participate in Upcoming Investor Conferences - GlobeNewswire

Nasus Pharma's NS002 Outperformed EpiPen® in Phase 2. Has the Market Caught Up? - Barchart.com

NSRX: Nasus Pharma Ltd. Latest Stock Price, Analysis, News and Trading Ideas - Stocktwits

Nasus Pharma (NSRX) Stock Forecast and Price Target 2026 - MarketBeat

Nasus Pharma Advances NS002 Towards Pivotal Study Following - GlobeNewswire

Nasus Pharma Advances NS002 Towards Pivotal Study Following Positive Phase 2; Reports Annual Results and Provides Business Update - Yahoo Finance

Nasus Pharma Announces Positive Top Line Data from Phase 2 Clinical Study of NS002: Achieves Significantly Superior and Faster Epinephrine Delivery Compared to EpiPen® with Accelerated Speed to Therapeutic Threshold - GlobeNewswire

Nasus Pharma: Recent Market Movements and Stock Analysis - Timothy Sykes

Nasus Pharma to Present Topline Analysis from NS002 - GlobeNewswire

Nasus Pharma to Present and Participate in the Upcoming Life Sciences Investor Forum - GlobeNewswire

Ähnlich wie NSRX

MIRA$0.54854.04%

SCLX$1.8510.19%

MDCX$1.8812.56%

AMRN$12.114.91%